We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GC Medical Science corp.

Download Mobile App




Sensory Shoe Insoles Help Prevent Diabetic Foot Ulcers

By HospiMedica International staff writers
Posted on 16 Dec 2019
Novel insoles assist management and prevention of diabetic foot ulcers (DFUs) through advanced foot sensor technology and real-time analytics.

The Orpyx (Calgary, Canada) SI Sensory Insoles with remote patient monitoring are designed to prevent DFUs and other neuropathy-related ulcers in the soles of the feet by monitoring pressure, temperature, and movement, and providing the wearer with real-time audiovisual alerts of pending high-pressure areas that may lead to tissue breakdown. More...
Each set of insoles are custom made and designed to effortlessly capture plantar pressure, temperature, and movement data throughout the day. Magnetic charging USB cables and an instruction manual are included with each pair of insoles.

Through a cloud-based dashboard, healthcare providers can monitor real-world data and identify trends to proactively make treatment decisions in order to keep their patients' feet healthy. In clinical studies, when compared to standard of care, Orpyx SI technology reduced DFU recurrence by up to 86% for people with diabetic peripheral neuropathy and a previous DFU. The technology can also be used to access clinical-grade plantar pressure data for health and human performance applications in the fields of sports medicine, therapeutic applications, and footwear design.

“It is our mission to eliminate preventable DFUs; current treatments are not enough. One in four people suffering from diabetes will develop a foot ulcer, and after the ulcer has healed, 40% of those will recur within the first year,” said Breanne Everett, MD, CEO of Orpyx and co-inventor of the insoles. “Once a person develops a DFU, the 5-year mortality rate is almost 50%, higher than leukemia, colon cancer, and breast cancer. In my clinical practice, I saw the physical and emotional toll DFUs had on our patients and their families. If we can prevent DFUs from recurring, we can greatly improve peoples' lives while avoiding costs.”

Diabetes patients often suffer from nerve and circulation problems in the feet, which reduce their perception of pain. The nerve pathways that ensure that weight is automatically transferred from one foot to the other during prolonged standing are disrupted, and as a result, diabetics do not notice that their toes, heels, or the balls of their feet are too heavily loaded. The foot receives no relief, and pressure sores, DFUs, and infections may go unnoticed. Serious cases may even lead to amputation.

Related Links:
Orpyx


Gold Member
12-Channel ECG
CM1200B
Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
New
Electrically Operated Patient Lifter
SVL 205
New
Steam Sterilizer
AMSCO 400 Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Business

view channel
Image: A research collaboration aims to further advance findings in human genomics research in cardiovascular diseases (Photo courtesy of 123RF)

Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies

A research collaboration will focus on the joint discovery of novel therapeutic approaches based on findings in human genomics research related to cardiovascular diseases. Bayer (Berlin, Germany) and... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.